Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies?

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 333-338

  Porta, Camillo ^a,b   Paglino, Chiara ^a,b   Imarisio, Ilaria ^a,b   Ganini, Carlo ^a   Pedrazzoli, Paolo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Italian Nephro Oncology Group   (Italy)

Author keywords

Cellular therapies; Immunology; Kidney cancer; Multikinase inhibitors

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; SORAFENIB; SUNITINIB;

CD4+ CD25+ T LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; KIDNEY CANCER; NATURAL KILLER CELL; NONHUMAN; REVIEW;

EID: 84866874594     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.333     Document Type: Review

References (40)

1. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003; 4: 385-90.
2. Naito S, Koga H, Yokomizo A, et al. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J Surg. 2000; 24: 1183-6.
3. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000; 163: 408-17.
4. Enquist E, Zambiano N, Zbar B, et al. Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Bukowski RM, Novick AC, eds. Renal cell carcinoma. Molecular biology, immunology and clinical management. Totowa, NJ (USA): Humana Press; 2000: 63-78.
5. Porta C, Bonomi L, Lillaz B, et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and of circulating dendritic cells in patients at first diagnosis. Anticancer Res. 2007; 27: 165-73.
6. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34.
7. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24.
8. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010; 28: 1061-8.
9. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007; 370: 2103-11.
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-81.
11. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-56.
12. Vogelzang NJ. Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol. 2006; 2: 1-3.
13. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007; 25: 3288-95.
14. Ryan CW, Goldman BH, Lara PN Jr, et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol. 2007; 25: 3296-301.
15. Jonasch E, Corn P, Pagliaro LC, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010; 116: 57-65.
16. Bracarda S, Porta C, Boni C, et al. Randomized prospective phase II trial of two schedules of Sorafenib daily and Interferon-α2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681. Genitourinary Cancers Symposium 2008;: abs357.
17. Procopio G, Verzoni E, Bracarda S, et al. Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer. 2011; 104: 1256-61.
18. Porta C, Imarisio I, Paglino C, Ferraris E, Tagliani F. Kinase inhibitors and the immune system: friend or foe? Oncol Rev. 2008; 2 (Suppl.1): S43-5.
19. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-109.
20. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood. 2008; 111: 5610-20.
21. Lebre MC, Burwell T, Vieira PL, et al. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol. 2005; 83: 525-35.
22. Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol. 2009; 183: 8286-94.
23. Molhoek KR, McSkimming CC, Olson WC, Brautigan DL, Slingluff CL Jr. Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunol Immunother. 2009; 58: 867-76.
24. Porta C, Paglino C, Imarisio I, Ferraris E. Sorafenib tosylate in advanced kidney cancer: past, present and future. Anticancer Drugs. 2009; 20: 409-15.
25. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs. 2009; 69: 223-40.
26. Duntas LH, Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid. 2010; 20: 1351-8.
27. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007; 25: 884-96.
28. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008; 14: 6674-82.
29. Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008; 14: 8270-8.
30. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009; 15: 2148-57.
31. Ozao-Choy J, Ma G, Kao J, et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009; 69: 2514-22.
32. van Cruijsen H, van der Veldt AA, Vroling L, et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res. 2008; 14: 5884-92.
33. Gu Y, Zhao W, Meng F, et al. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol. 2010; 135: 55-62.
34. Alberola-Ila J, Hernández-Hoyos G. The Ras/MAPK cascade and the control of positive selection. Immunol Rev. 2003; 191: 79-96.
35. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007; 5: 32.
36. Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother. 2007; 56: 761-70.
37. Porta C, Paglino C, Imarisio I, Bonomi L. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Scientific World Journal. 2007; 7: 837-49.
38. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343: 750-8.
39. Takahashi Y, Harashima N, Kajigaya S, et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest. 2008; 118: 1099-109.
40. Porta C. Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses. Oncol Rev. 2008; 2: 1-3.